MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.28
+0.65
+2.12%
After Hours: 31.00 -0.28 -0.90% 19:06 09/17 EDT
OPEN
30.69
PREV CLOSE
30.63
HIGH
31.41
LOW
29.93
VOLUME
2.79M
TURNOVER
--
52 WEEK HIGH
56.74
52 WEEK LOW
21.06
MARKET CAP
4.47B
P/E (TTM)
-11.4865
1D
5D
1M
3M
1Y
5Y
TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ETNEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of upcoming data pres...
GlobeNewswire · 6d ago
TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive O...
GlobeNewswire · 09/09 13:00
The five-year returns have been fantastic for TG Therapeutics (NASDAQ:TGTX) shareholders despite underlying losses increasing
It hasn't been the best quarter for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, since the share price has...
Simply Wall St. · 09/03 17:11
TG Therapeutics Announces Data Presentations At Upcoming XIX International Workshop On Chronic Lymphocytic Leukemia Sept. 17-20
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 –
Benzinga · 08/30 11:31
TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 - 20, 2021. Details of the data presentation...
GlobeNewswire · 08/30 11:30
Understanding TG Therapeutics's Unusual Options Activity
TG Therapeutics (NASDAQ:TGTX) shares experienced unusual options activity on Monday. The stock price moved down to $22.62 following the option alert.
Benzinga · 08/16 17:04
Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't?
Zacks.com · 08/16 14:15
Looking into TG Therapeutics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, TG Therapeutics (NASDAQ:TGTX) posted sales of $1.54 million. Earnings were up 13.36%, but TG Therapeutics still reported an overall loss of $76.87 million.
Benzinga · 08/13 14:50
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TGTX. Analyze the recent business situations of TG Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TGTX stock price target is 59.88 with a high estimate of 84.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 300
Institutional Holdings: 113.00M
% Owned: 79.11%
Shares Outstanding: 142.83M
TypeInstitutionsShares
Increased
85
5.81M
New
43
3.05M
Decreased
70
10.00M
Sold Out
46
1.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Weiss
Chief Financial Officer/Treasurer/Secretary
Sean Power
Lead Director/Independent Director
Laurence Charney
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
William Kennedy
Independent Director
Sagar Lonial
No Data
About TGTX
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.